Showing results (121-130 of 163) with videos related to

Sort By:
Pageof 17
Molecular Therapy. Nucleic Acids|May 10, 2019
Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung AdenocarcinomaRui Chen, Wenjia Xia, Siwei Wang, et al.
Acta Oncologica (Stockholm, Sweden)|August 9, 2020
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumabAlex Friedlaender, Giulio Metro, Diego Signorelli, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2026
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP studyMaria Gemelli, Luca Sala, Alessandro Morabito, et al.
Genes|May 5, 2021
Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with <i>EGFR</i> Exon 20 Insertion MutationsGiulio Metro, Sara Baglivo, Guido Bellezza, et al.
Journal of Thoracic Disease|February 8, 2020
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohortGiulio Metro, Alfredo Addeo, Diego Signorelli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.
Future Oncology (London, England)|July 25, 2019
ASTRIS: a global real-world study of osimertinib in >3000 patients with <i>EGFR</i> T790M positive non-small-cell lung cancerFilippo de Marinis, Yi-Long Wu, Gilberto de Castro, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2022
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)Antonio Passaro, Giuseppe Lo Russo, Francesco Passiglia, et al.
Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2025
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT TrialFederico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, et al.
Pageof 17